Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

PRRT as neoadjuvant treatment in NET.

Sowa-Staszczak A, Hubalewska-Dydejczyk A, Tomaszuk M.

Recent Results Cancer Res. 2013;194:479-85. doi: 10.1007/978-3-642-27994-2_27.

PMID:
22918777
2.

Polish experience in Peptide receptor radionuclide therapy.

Kunikowska J, Królicki L, Sowa-Staszczak A, Hubalewska-Dydejczyk A, Pawlak D, Mikolajczak R, Handkiewicz-Junak D, Szaluś N, Kamiński G, Cwikla J, Jakuciński M, Lukiewicz A, Kowalska A, Gut P.

Recent Results Cancer Res. 2013;194:467-78. doi: 10.1007/978-3-642-27994-2_26.

PMID:
22918776
3.

4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine.

Kairemo K, Kangasmäki A.

Recent Results Cancer Res. 2013;194:537-50. doi: 10.1007/978-3-642-27994-2_31.

PMID:
22918781
4.

Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.

Pach D, Sowa-Staszczak A, Kunikowska J, Królicki L, Trofimiuk M, Stefańska A, Tomaszuk M, Głowa B, Mikołajczak R, Pawlak D, Jabrocka-Hybel A, Hubalewska-Dydejczyk AB.

Radiother Oncol. 2012 Jan;102(1):45-50. doi: 10.1016/j.radonc.2011.08.006. Epub 2011 Aug 30.

PMID:
21885142
5.

[Peptide receptor radionuclide therapy of neuroendocrine tumors].

Arveschoug AK, Hjorthaug K, Rehling M, Højgaard L, Mortensen J, Oturai PS.

Ugeskr Laeger. 2009 Mar 23;171(13):1073. Danish. No abstract available.

PMID:
19321068
6.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.

Semin Nucl Med. 2002 Apr;32(2):133-40. Review.

PMID:
11965608
7.

The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.

Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP.

Recent Results Cancer Res. 2013;194:519-36. doi: 10.1007/978-3-642-27994-2_30.

PMID:
22918780
8.

Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.

Kulkarni HR, Schuchardt C, Baum RP.

Recent Results Cancer Res. 2013;194:551-9. doi: 10.1007/978-3-642-27994-2_32.

PMID:
22918782
9.

Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.

Todorović-Tirnanić M, Kaemmerer D, Prasad V, Hommann M, Baum RP.

Recent Results Cancer Res. 2013;194:487-96. doi: 10.1007/978-3-642-27994-2_28.

PMID:
22918778
10.

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP.

Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73. doi: 10.1677/ERC-09-0078. Print 2010 Mar. Review.

11.

Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

Kwekkeboom DJ, de Herder WW, Krenning EP.

Endocrinol Metab Clin North Am. 2011 Mar;40(1):173-85, ix. doi: 10.1016/j.ecl.2010.12.003. Review.

PMID:
21349418
12.

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.

Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, Krenning EP, Kwekkeboom DJ.

Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):867-81. doi: 10.1016/j.bpg.2013.01.004.

PMID:
23582925
13.

Lutetium-labelled peptides for therapy of neuroendocrine tumours.

Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S103-12. doi: 10.1007/s00259-011-2039-y. Review.

14.

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.

Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O'Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A.

Pancreas. 2014 May;43(4):518-25. doi: 10.1097/MPA.0000000000000113.

PMID:
24632546
15.

Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT.

Makis W, McCann K, McEwan AJ.

Clin Nucl Med. 2015 May;40(5):e278-81. doi: 10.1097/RLU.0000000000000733.

PMID:
25783505
16.

Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.

Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R.

Ann Oncol. 1999;10 Suppl 2:S23-9.

PMID:
10399029
17.

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.

Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, Visser TJ, Krenning EP.

Eur J Nucl Med. 2001 Sep;28(9):1421-9. Review.

PMID:
11585303
18.

Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.

Kulkarni HR, Baum RP.

PET Clin. 2014 Jan;9(1):83-90. doi: 10.1016/j.cpet.2013.08.015. Review.

PMID:
25029937
19.

Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.

Campana D, Capurso G, Partelli S, Nori F, Panzuto F, Tamburrino D, Cacciari G, Delle Fave G, Falconi M, Tomassetti P.

Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1197-205. doi: 10.1007/s00259-013-2402-2. Epub 2013 Apr 26.

PMID:
23619938
20.

Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.

Bodei L, Pepe G, Paganelli G.

Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):347-51. Review.

PMID:
20496546
Items per page

Supplemental Content

Write to the Help Desk